124
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is a rare but often severe autoimmune disease with median onset around 40 years of age. We report characteristics of three very-late-onset NMOSD (including complete NMO) patients >75 years of age, in whom this diagnosis initially seemed unlikely because of their age and age-associated concomitant diseases, and briefly review the literature. All three patients, aged 79, 82 and 88 years, presented with a spinal cord syndrome as the first clinical manifestation of AQP4-Ab-positive NMOSD. They all had severe relapses unless immunosuppressive therapy was initiated, and one untreated patient died of a fatal NMOSD course. Two patients developed side effects of immunosuppression. We conclude that a first manifestation of NMOSD should be considered even in patients beyond the age of 75 years with a compatible syndrome, especially longitudinally extensive myelitis. Early diagnosis and treatment are feasible and highly relevant. Special attention is warranted in the elderly to recognize adverse effects of immunosuppressive therapies as early as possible.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

          Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%). Results Seropositive patients were found to be predominantly female (p 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome. Conclusion This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Seroprevalence of autoantibodies against brain antigens in health and disease.

            We previously reported an unexpectedly high seroprevalence (~10%) of N-methyl-D-aspartate-receptor subunit-NR1 (NMDAR1) autoantibodies (AB) in healthy and neuropsychiatrically ill subjects (N = 2,817). This finding challenges an unambiguous causal relationship of serum AB with brain disease. To test whether similar results would be obtained for other brain antigen-directed AB previously connected with pathological conditions, we systematically screened serum samples of 4,236 individuals. Serum samples of healthy (n = 1,703) versus neuropsychiatrically ill subjects (schizophrenia, affective disorders, stroke, Parkinson disease, amyotrophic lateral sclerosis, personality disorder; total n = 2,533) were tested. For analysis based on indirect immunofluorescence, we used biochip mosaics of frozen brain sections (rat, monkey) and transfected HEK293 cells expressing respective recombinant target antigens. Seroprevalence of all screened AB was comparable in healthy and ill individuals. None of them, however, reached the abundance of NMDAR1 AB (again ~10%; immunoglobulin [Ig] G ~1%). Appreciable frequency was noted for AB against amphiphysin (2.0%), ARHGAP26 (1.3%), CASPR2 (0.9%), MOG (0.8%), GAD65 (0.5%), Ma2 (0.5%), Yo (0.4%), and Ma1 (0.4%), with titers and Ig class distribution similar among groups. All other AB were found in ≤0.1% of individuals (anti-AMPAR-1/2, AQP4, CV2, Tr/DNER, DPPX-IF1, GABAR-B1/B2, GAD67, GLRA1b, GRM1, GRM5, Hu, LGl1, recoverin, Ri, ZIC4). The predominant Ig class depended on antigen location, with intracellular epitopes predisposing to IgG (chi-square = 218.91, p = 2.8 × 10(-48) ). To conclude, the brain antigen-directed AB tested here are comparably detectable in healthy subjects and the disease groups studied here, thus questioning an upfront pathological role of these serum AB. © 2014 American Neurological Association.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.

              Rare diseases require integrated multicenter clinical networks to facilitate clinical research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that are distinct from multiple sclerosis and associated with NMO-IgG, a serologic antibody against aquaporin 4. To develop a national multicenter NMO clinical consortium and report initial demographic, clinical, and radiographic features of a cohort of patients with NMO/NMOSD in the United States. Review of medical records from patients undergoing evaluation during a 5-year period. We used uniform diagnostic criteria and clinical, laboratory, and neuroimaging definitions to describe the cohort. Three academic medical centers. One hundred eighty-seven patients with NMO/NMOSD. Of the 187 patients included in the analysis, 86 had NMO-IgG-seropositive NMO; 40, NMO-IgG-seronegative NMO; and 61, NMO-IgG-seropositive NMOSD. Altogether, 29.4% of our patients were initially misdiagnosed with multiple sclerosis. The average age at onset of NMO/NMOSD was 41.1 years with a strong female predilection, similar to other autoimmune disorders. Nonwhite patients constituted 52.4% of the cohort. The hallmark of NMO and NMOSD is recurrent longitudinally extensive transverse myelitis, but patients with NMO tend to initially present with optic neuritis. A national multicenter consortium to study NMO/NMOSD is feasible and facilitates accurate clinical diagnosis. This network establishes a foundation for determining disease prevalence, translational research, and clinical trials.
                Bookmark

                Author and article information

                Contributors
                +49 89 4400-78382 , markus.krumbholz@med.uni-muenchen.de
                u.hofstadt@gmx.de
                klemens.angstwurm@medbo.de
                ingo.kleiter@ruhr-uni-bochum.de
                sven.jarius@med.uni-heidelberg.de
                Friedemann.Paul@charite.de
                orhan.aktas@uni-duesseldorf.de
                grete.buchholz@med.uni-muenchen.de
                pe.kern@asklepios.com
                andreas.straube@med.uni-muenchen.de
                tania.kuempfel@med.uni-muenchen.de
                Journal
                J Neurol
                J. Neurol
                Journal of Neurology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0340-5354
                1432-1459
                10 May 2015
                10 May 2015
                2015
                : 262
                : 5
                : 1379-1384
                Affiliations
                [ ]Institute of Clinical Neuroimmunology, Ludwig Maximilian University, Max-Lebsche-Platz 31, 81377 Munich, Germany
                [ ]Klinik für Neurologie, Klinikum Bayreuth—Klinik Hohe Warte, Bayreuth, Germany
                [ ]Department of Neurology, University of Regensburg, Regensburg, Germany
                [ ]Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany
                [ ]Molecular Neuroimmunology Group, Dpt. of Neurology, University of Heidelberg, Heidelberg, Germany
                [ ]NeuroCure Clinical Research Center and Department of Neurology, Charité University Medicine Berlin, Berlin, Germany
                [ ]Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
                [ ]Department of Neurology, Ludwig Maximilian University, Munich, Germany
                [ ]Klinik für Neurologie und Klinische Neurophysiologie, Asklepios Fachklinikum, Teupitz, Germany
                Article
                7766
                10.1007/s00415-015-7766-8
                4441737
                25957640
                867bc2f5-3c85-4b97-8c40-20c99a941fc6
                © The Author(s) 2015

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 17 March 2015
                : 20 April 2015
                : 21 April 2015
                Categories
                Short Commentary
                Custom metadata
                © Springer-Verlag Berlin Heidelberg 2015

                Neurology
                neuromyelitis optica (devic syndrome),myelitis,aquaporin 4 antibodies,very late-onset,elderly/old-age,therapy/immunosuppression

                Comments

                Comment on this article